Velnacrine for Alzheimer's disease.

Journal article

BACKGROUND: Alzheimer's disease (AD) is the commonest cause of dementia affecting older people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in relevant parts of the brain by the use of cholinesterase inhibitors to delay the breakdown of acetylcholine released into synaptic clefts. Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was assoc...

Expand abstract

Authors: Birks, J; Wilcock, G

• Journal: Cochrane database of systematic reviews
• Issue: 2
• Pages: CD004748
• Publication date: 2004-01-01
• DOI: 10.1002/14651858.cd004748
• EISSN: 1469-493X
• Language: English
• Keywords: Randomized Controlled Trials as Topic; Alzheimer Disease; Cholinesterase Inhibitors; Tacrine; Humans